Press Releases

18th December 2020
COVID-19 Clinical Programme Update

13th November 2020
Lancet Respiratory Medicine publishes Phase 2 data

2nd November 2020
Result of General Meeting and Total Voting Rights

2nd November 2020
Result of Open Offer

15th October 2020
Results of Placing

14th October 2020
Placing and Open Offer

2nd October 2020
Appointment of Joint Broker

29th September 2020
Interim results for the six months ended 30 June 2020

29th September 2020
Synairgen and Clinigen sign Managed Access Program agreement with SNG001 for treatment of hospitalised patients with COVID-19

9th September 2020
Synairgen IP Update

8th September 2020
Positive interim analysis of SNG001 in COPD

21st July 2020
Clarification Regarding COVID-19 Trial

20th July 2020
Positive results from trial of SNG001 in hospitalised COVID-19 patients

29th June 2020
Result of AGM

18th June 2020
National expansion of home-based COVID-19 trial

3rd June 2020
Posting of Annual Report and Notice of AGM

28th May 2020
Recruitment of Hospitalised Patients in COVID-19 Trial Completed

26th May 2020
Initiation of SNG001 in home setting

26th May 2020
Preliminary statement of results for the year ended 31 December 2019

30th April 2020
Approval received to extend SG016 study of SNG001 in COVID-19 to initiate patients in the home environment

14th April 2020
Result of General Meeting

31st March 2020
Commencement of dosing in COVID-19 trial

26th March 2020
Result of fundraising

25th March 2020
Proposed fundraising

18th March 2020
Synairgen to start trial of SNG001 in COVID-19 imminently

30th September 2019
Interim results for the six months ended 30 June 2019

27th September 2019
Phase II Biomarker Data for SNG001 to be presented at European Respiratory Society

24th July 2019
Phase II Clinical Trial Update in Patients with COPD

3rd June 2019
Result of AGM

18th April 2019
Directorate Change, Posting of Annual Report, and Notice of AGM

14th March 2019
Positive DSMC Review of Phase II Study for SNG001

25th February 2019
Preliminary statement of results for the year ended 31 December 2018

17th January 2019
Update on LOXL2 programme with Pharmaxis

22nd October 2018
Synairgen commences dosing in part 2 of its Phase II clinical trial in patients with COPD

12th October 2018
Result of General Meeting

25th September 2018
Result of Fundraise

25th September 2018
Proposed Fundraise to raise c.£2.9 million

25th September 2018
Interim results for the six months ended 30 June 2018

28th June 2018
Positive SNG001 Biomarker Data in COPD Patients

22nd June 2018
Result of Synairgen AGM

22nd June 2018
Synairgen Safety Data with SNG001 in COPD Patients

17th May 2018
Posting of Annual Report and Notice of AGM

15th March 2018
Preliminary statement of results for the year ended 31 December 2017

7th February 2018
Synairgen starts dosing in phase II COPD study

27th December 2017
Data update from clinical trial of inhaled interferon beta (SNG001) and clinical plan for COPD

14th December 2017
Update on LOXL2 Programme and Collaboration with Pharmaxis

27th September 2017
Interim results for the six months ended 30 June 2017

6th September 2017
LOXL2 Inhibitor Update

28th June 2017
Result of 2017 Annual General Meeting

5th June 2017
Posting of Annual Report and Notice of AGM

17th May 2017
Preliminary statement of results for the year ended 31 December 2016

27th April 2017
AZD9412 Update

10th March 2017
Additional Positive Data in Lung Fibrosis

12th October 2016
AZD9412 Clinical Trial Update

22nd September 2016
Interim results for the six months ended 30 June 2016

8th September 2016
Notice of Interim Results

14th June 2016
Results of 2016 Annual General Meeting

17th May 2016
Posting of Annual Report and Notice of AGM

22nd March 2016
Preliminary statement of results for the year ended 31 December 2015

22nd March 2016
Positive LOXL2 results

3rd March 2016
Notice of Preliminary Results

16th September 2015
Interim results for the six months ended 30 June 2015

21st August 2015
Notice of Interim Results

5th August 2015
Research collaboration with Pharmaxis in IPF

2nd July 2015
AstraZeneca commences AZD9412 Phase II trial in severe asthma

22nd June 2015
Results of 2015 Annual General Meeting

15th May 2015
Notice of Annual General Meeting

22nd April 2015
Posting of Annual Report and Accounts

3rd March 2015
Preliminary statement of results for the year ended 31 December 2014

25th September 2014
Interim results for the six months ended 30 June 2014

17th September 2014
Notice of Interim Results